HALO Director, Professor Mark Tremblay, was in Scandinavia October 2-13 for research meetings and presentations in Copenhagen, Denmark (Steno Diabetes Center; Novo Nordisk Foundation), Stockholm, Sweden (Karolinska Institute) and Helsinki, Finland (University of Helsinki).